Mood-stabilizers target the brain arachidonic acid cascade

Current Molecular Pharmacology

Volumn 2, Issue 2, 2009, Pages 207-214

  Rao, Jagadeesh S ^a   Rapoport, Stanley I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

AP 2; Arachidonic acid; Bipolar disorder; COX 2; cPLA2; Mood stabilizers; NF kB; sPLA2

Indexed keywords

ARACHIDONIC ACID; CARBAMAZEPINE; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; DOCOSAHEXAENOIC ACID; FLUOXETINE; IMIPRAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; PROSTAGLANDIN E2; TOPIRAMATE; TRANSCRIPTION FACTOR AP 2; VALPROIC ACID; ANTIDEPRESSANT AGENT; PHOSPHOLIPASE A2 GROUP IV; TRANQUILIZER;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; FATTY ACID METABOLISM; HUMAN; MANIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BRAIN; DRUG EFFECT; METABOLISM; RAT; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ARACHIDONIC ACID; BIPOLAR DISORDER; BRAIN; CYCLOOXYGENASE 2; GROUP IV PHOSPHOLIPASES A2; NF-KAPPA B; RATS; TRANSCRIPTION FACTOR AP-2;

EID: 77449095540     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467210902020207     Document Type: Article

References (111)

1. Judd, L. L.; Akiskal, H. S. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 2003, 73, 123-131.
2. Bostwick, J. M.; Pankratz, V. S. Affective disorders and suicide risk: a reexamination. Am. J. Psychiatry 2000, 157, 1925-1932.
3. Chang, A.; Li, P. P.; Warsh, J. J. Altered cAMP-dependent protein kinase subunit immunolabeling in post-mortem brain from patients with bipolar affective disorder. J. Neurochem. 2003, 84, 781-791.
4. Rajkowska, G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry 2000, 48, 766-777.
5. Brauch, R. A.; Adnan El-Masri, M.; Parker, J. C., Jr.; El-Mallakh, R. S. Glial cell number and neuron/glial cell ratios in postmortem brains of bipolar individuals. J. Affect. Disord. 2006, 91, 87-90.
6. Lyoo, I. K.; Kim, M. J.; Stoll, A. L.; Demopulos, C. M.; Parow, A. M.; Dager, S. R.; Friedman, S. D.; Dunner, D. L.; Renshaw, P. F. Frontal lobe gray matter density decreases in bipolar I disorder. Biol. Psychiatry 2004, 55, 648-651.
7. Lyoo, I. K.; Sung, Y. H.; Dager, S. R.; Friedman, S. D.; Lee, J. Y.; Kim, S. J.; Kim, N.; Dunner, D. L.; Renshaw, P. F. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord. 2006, 8, 65-74.
8. Rajkowska, G. Cell pathology in bipolar disorder. Bipolar Disord. 2002, 4, 105-116.
9. Baum, A. E.; Akula, N.; Cabanero, M.; Cardona, I.; Corona, W.; Klemens, B.; Schulze, T. G.; Cichon, S.; Rietschel, M.; Nothen, M. M.; Georgi, A.; Schumacher, J.; Schwarz, M.; Abou Jamra, R.; Hofels, S.; Propping, P.; Satagopan, J.; Detera-Wadleigh, S. D.; Hardy, J.; McMahon, F. J. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry 2008, 13, 197-207.
10. Manji, H. K.; Duman, R. S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol. Bull. 2001, 35, 5-49.
11. Mueller, H. T.; Meador-Woodruff, J. H. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr. Res. 2004, 71, 361-370.
12. Mundo, E.; Tharmalingham, S.; Neves-Pereira, M.; Dalton, E. J.; Macciardi, F.; Parikh, S. V.; Bolonna, A.; Kerwin, R. W.; Arranz, M. J.; Makoff, A. J.; Kennedy, J. L. Evidence that the N-methyl-Daspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol. Psychiatry 2003, 8, 241-245.
13. Nudmamud-Thanoi, S.; Reynolds, G. P. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci. Lett. 2004, 372, 173-177.
14. Beneyto, M.; Kristiansen, L. V.; Oni-Orisan, A.; McCullumsmith, R. E.; Meador-Woodruff, J. H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32, 1888-1902.
15. Kim, Y. K.; Jung, H. G.; Myint, A. M.; Kim, H.; Park, S. H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007, 104, 91-95.
16. O'Brien, S. M.; Scully, P.; Scott, L. V.; Dinan, T. G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 2006, 90, 263-267.
17. Basselin, M.; Chang, L.; Bell, J. M.; Rapoport, S. I. Chronic Lithium Chloride Administration Attenuates Brain NMDA Receptor-Initiated Signaling via Arachidonic Acid in Unanesthetized Rats. Neuropsychopharmacology 2005, 30, 1064-1075.
18. Matsumoto, Y.; Yamaguchi, T.; Watanabe, S.; Yamamoto, T. Involvement of arachidonic acid cascade in working memory impairment induced by interleukin-1 beta. Neuropharmacology 2004, 46, 1195-1200.
19. Lee, H. J.; Rao, J. S.; Chang, L.; Rapoport, S. I.; Bazinet, R. P. Chronic N-methyl-D-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat. J. Lipid Res. 2008, 49, 162-168.
20. Garrido, R.; Springer, J. E.; Hennig, B.; Toborek, M. Apoptosis of spinal cord neurons by preventing depletion nicotine attenuates arachidonic acid-induced of neurotrophic factors. J. Neurotrauma 2003, 20, 1201-1213.
21. Ong, W. Y.; Sandhya, T. L.; Horrocks, L. A.; Farooqui, A. A. Distribution of cytoplasmic phospholipase A2 in the normal rat brain. J. Hirnforsch. 1999, 39, 391-400.
22. Akiba, S.; Mizunaga, S.; Kume, K.; Hayama, M.; Sato, T. Involvement of group VI Ca2+-independent phospholipase A2 in protein kinase C-dependent arachidonic acid liberation in zymosan-stimulated macrophage-like P388D1 cells. J. Biol. Chem. 1999, 274, 19906-19912.
23. Murakami, M.; Kambe, T.; Shimbara, S.; Kudo, I. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J. Biol. Chem. 1999, 274, 3103-3115.
24. Murakami, M.; Kudo, I. Phospholipase A2. J. Biochem.(Tokyo) 2002, 131, 285-292.
25. Murakami, M.; Shimbara, S.; Kambe, T.; Kuwata, H.; Winstead, M. V.; Tischfield, J. A.; Kudo, I. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J. Biol. Chem. 1998, 273, 14411-14423.
26. Yang, H. C.; Mosior, M.; Johnson, C. A.; Chen, Y.; Dennis, E. A. Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal. Biochem. 1999, 269, 278-288.
27. Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294, 1871-1875.
28. Seibert, K.; Masferrer, J.; Zhang, Y.; Gregory, S.; Olson, G.; Hauser, S.; Leahy, K.; Perkins, W.; Isakson, P. Mediation of inflammation by cyclooxygenase-2. Agents Actions. Suppl. 1995, 46, 41-50.
29. Pepicelli, O.; Fedele, E.; Bonanno, G.; Raiteri, M.; Ajmone-Cat, M. A.; Greco, A.; Levi, G.; Minghetti, L. In vivo activation of N-methyl-D-aspartate receptors in the rat hippocampus increases prostaglandin E(2) extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms. J. Neurochem. 2002, 81, 1028-1034.
30. Appleby, S. B.; Ristimaki, A.; Neilson, K.; Narko, K.; Hla, T. Structure of the human cyclo-oxygenase-2 gene. Biochem. J. 1994, 302(Pt 3), 723-727.
31. Morri, H.; Ozaki, M.; Watanabe, Y. 5'-flanking region surrounding a human cytosolic phospholipase A2 gene. Biochem. Biophys. Res. Commun. 1994, 205, 6-11.
32. Kam, P. C.; See, A. U. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 2000, 55, 442-449.
33. Leslie, J. B.; Watkins, W. D. Eicosanoids in the central nervous system. J. Neurosurg. 1985, 63, 659-668.
34. O'Banion, M. K. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol. 1999, 13, 45-82.
35. Hibbeln, J. R.; Palmer J. W.; Davis, J. M. Are disturbances in lipidprotein interactions by phospholipase-A2 a predisposing factor in affective illness? Biol. Psychiatry 1989, 25, 945-961.
36. Lieb, J.; Karmali, R.; Horrobin, D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins. Leukot. Med. 1983, 10, 361-367.
37. Sublette, M. E.; Russ, M. J.; Smith, G. S. Evidence for a role of the arachidonic acid cascade in affective disorders: a review. Bipolar Disord. 2004, 6, 95-105.
38. Nishino, S.; Ueno, R.; Ohishi, K.; Sakai, T.; Hayaishi, O. Salivary prostaglandin concentrations: possible state indicators for major depression. Am. J. Psychiatry 1989, 146, 365-368.
39. Linnoila, M.; Whorton, A. R.; Rubinow, D. R.; Cowdry, R. W.; Ninan, P. T.; Waters, R. N. CSF prostaglandin levels in depressed and schizophrenic patients. Arch. Gen. Psychiatry 1983, 40, 405-406.
40. Jacobsen, N. J.; Franks, E. K.; Owen, M. J.; Craddock, N. J. Mutational analysis of phospholipase A2A: a positional candidate susceptibility gene for bipolar disorder. Mol. Psychiatry 1999, 4, 274-279.
41. Basselin, M.; Villacreses, N. E.; Chen, M.; Bell, J. M.; Rapoport, S. I. Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain. Biol. Psychiatry 2007, 62, 934-943.
42. Rao, J. S.; Ertley, R. N.; DeMar, J. C., Jr.; Rapoport, S. I.; Bazinet, R. P.; Lee, H. J. Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol. Psychiatry 2007, 12, 151-157.
43. Sherman, W. R.; Leavitt, A. L.; Honchar, M. P.; Hallcher, L. M.; Phillips, B. E. Evidence that lithium alters phosphoinositide metabolism: chronic administration elevates primarily D-myoinositol-1-phosphate in cerebral cortex of the rat. J. Neurochem. 1981, 36, 1947-1951.
44. Jacobsen, F. M. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J. Clin. Psychiatry 1993, 54, 229-234.
45. Wang, H. Y.; Friedman, E. Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes. Neuropharmacology 1999, 38, 403-414.
46. Miki, M.; Hamamura T.; Ujike, H.; Lee, Y.; Habara, T.; Kodama, M.; Ohashi, K.; Tanabe, Y.; Kuroda, S. Effects of subchronic lithium chloride treatment on G-protein subunits (Golf, Ggamma7) and adenylyl cyclase expressed specifically in the rat striatum. Eur. J. Pharmacol. 2001, 428, 303-309.
47. Mork, A. Actions of lithium on the cyclic AMP signalling system in various regions of the brain--possible relations to its psychotropic actions. A study on the adenylate cyclase in rat cerebral cortex, corpus striatum and hippocampus. Pharmacol. Toxicol. 1993, 73(Suppl. 3), 1-47.
48. Mork, A.; Geisler, A. Effects of chronic lithium treatment on agonist-enhanced extracellular concentrations of cyclic AMP in the dorsal hippocampus of freely moving rats. J. Neurochem. 1995, 65, 134-139.
49. De Sarno, P.; Li, X.; Jope, R. S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43, 1158-1164.
50. Mori, S.; Tardito, D.; Dorigo, A.; Zanardi, R.; Smeraldi, E.; Racagni, G.; Perez, J. Effects of lithium on cAMP-dependent protein kinase in rat brain. Neuropsychopharmacology 1998, 19, 233-240.
51. Chen, G.; Pan, B.; Hawver, D. B.; Wright, C. B.; Potter, W. Z.; Manji, H. K. Attenuation of cyclic AMP production by carbamazepine. J. Neurochem. 1996, 67, 2079-2086.
52. Manji, H. K.; Etcheberrigaray, R.; Chen, G.; Olds, J. L. Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J. Neurochem. 1993, 61, 2303-2310.
53. Soares, J. C.; Chen, G.; Dippold, C. S.; Wells, K. F.; Frank, E.; Kupfer, D. J.; Manji, H. K.; Mallinger, A. G. Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals: a preliminary study. Psychiatry Res. 2000, 95, 109-118.
54. Chen, G.; Huang, L. D.; Jiang, Y. M.; Manji, H. K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 1999, 72, 1327-1330.
55. Lenox, R. H.; Watson, D. G.; Patel, J.; Ellis, J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 1992, 570, 333-340.
56. Watson, D. G.; Lenox, R. H. Chronic lithium-induced down regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J. Neurochem. 1996, 67, 767-777.
57. Chang, M. C.; Grange, E.; Rabin, O.; Bell, J. M.; Allen, D. D.; Rapoport, S. I. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci. Lett. 1996, 220, 171-174.
58. Rintala, J.; Seemann, R.; Chandrasekaran, K.; Rosenberger, T. A.; Chang, L.; Contreras, M. A.; Rapoport, S. I.; Chang, M. C. 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 1999, 10, 3887-3890.
59. Chang, M. C.; Bell, J. M.; Purdon, A. D.; Chikhale, E. G.; Grange, E. Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment. Neurochem. Res. 1999, 24, 399-406.
60. Bazinet, R. P.; Rao, J. S.; Chang, L.; Rapoport, S. I.; Lee, H. J. Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl). 2005, 182, 180-185.
61. Imagawa, M.; Chiu, R.; Karin, M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 1987, 51, 251-260.
62. Bosetti, F.; Rintala, J.; Seemann, R.; Rosenberger, T. A.; Contreras, M. A.; Rapoport, S. I.; Chang, M. C. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol. Psychiatry 2002, 7, 845-850.
63. Belmaker, R. H. Bipolar disorder. N. Engl. J. Med. 2004, 351, 476-486.
64. Bown, C. D.; Wang, J. F.; Young, L. T. Attenuation of N-methyl-D-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers. Neuroscience 2003, 117, 949-955.
65. Jakobsen, S. N.; Wiborg, O. Selective effects of long-term lithium and carbamazepine administration on G-protein subunit expression in rat brain. Brain Res. 1998, 780, 46-55.
66. Ghelardoni, S.; Tomita, Y. A.; Bell, J. M.; Rapoport, S. I.; Bosetti, F. Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol. Psychiatry 2004, 56, 248-254.
67. Bazinet, R. P.; Rao, J. S.; Chang, L.; Rapoport, S. I.; Lee, H. J. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol. Psychiatry 2006, 59, 401-407.
68. McElroy, S. L.; Keck, P. E., Jr.; Pope, H. G., Jr.; Hudson, J. I. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J. Clin. Psychopharmacol. 1992, 12, 42S-52S.
69. Klein, P. S.; Melton, D. A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 1996, 93, 8455-8459.
70. Chen, G.; Manji, H. K.; Hawver, D. B.; Wright, C. B.; Potter, W. Z. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J. Neurochem. 1994, 63, 2361-2364.
71. Manji, H. K.; Chen, G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol. Psychiatry 2002, 7(Suppl. 1), S46-56.
72. Chen, G.; Yuan, P.; Hawver, D. B.; Potter, W. Z.; Manji, H. K. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 1997, 16, 238-245.
73. Yuan, P. X.; Huang, L. D.; Jiang, Y. M.; Gutkind, J. S.; Manji, H. K.; Chen, G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 2001, 276, 31674-31683.
74. Phiel, C. J.; Zhang, F.; Huang, E. Y.; Guenther, M. G.; Lazar, M. A.; Klein, P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001, 276, 36734-36741.
75. Chang, M. C.; Contreras, M. A.; Rosenberger, T. A.; Rintala, J. J.; Bell, J. M.; Rapoport, S. I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem. 2001, 77, 796-803.
76. Bosetti, F.; Weerasinghe, G. R.; Rosenberger, T. A.; Rapoport, S. I. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J. Neurochem. 2003, 85, 690-696.
77. Szupera, Z.; Mezei, Z.; Kis, B.; Gecse, A.; Vecsei, L.; Telegdy, G. The effects of valproate on the arachidonic acid metabolism of rat brain microvessels and of platelets. Eur. J. Pharmacol. 2000, 387, 205-210.
78. Calabrese, J. R.; Bowden, C. L.; Sachs, G. S.; Ascher, J. A.; Monaghan, E.; Rudd, G. D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry 1999, 60, 79-88.
79. Calabrese, J. R.; Rapport, D. J.; Youngstrom, E. A.; Jackson, K.; Bilali, S.; Findling, R. L. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. Eur. Psychiatry 2005, 20, 92-95.
80. Hassel, B.; Tauboll, E.; Gjerstad, L. Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels. Epilepsy Res. 2001, 43, 153-163.
81. Ahmad, S.; Fowler, L. J.; Whitton, P. S. Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br. J. Pharmacol. 2004, 142, 136-142.
82. Ahmad, S.; Fowler, L. J.; Whitton, P. S. Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. Naunyn. Schmiedebergs Arch. Pharmacol. 2005, 371, 1-8.
83. Arban, R.; Maraia, G.; Brackenborough, K.; Winyard, L.; Wilson, A.; Gerrard, P.; Large, C. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav. Brain Res. 2005, 158, 123-132.
84. Bowden, C. L.; Calabrese, J. R.; Sachs, G.; Yatham, L. N.; Asghar, S. A.; Hompland, M.; Montgomery, P.; Earl, N.; Smoot, T. M.; DeVeaugh-Geiss, J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 2003, 60, 392-400.
85. Ross, B. M.; Hughes, B.; Kish, S. J.; Warsh, J. J. Serum calcium-independent phospholipase A2 activity in bipolar affective disorder. Bipolar Disord. 2006, 8, 265-270.
86. Basselin, M.; Chang, L.; Bell, J. M.; Rapoport, S. I. Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 2006, 31, 1659-1674.
87. Carta, M. G.; Hardoy, M. C.; Pilu, A.; Sorba, M.; Floris, A. L.; Mannu, F. A.; Baum, A.; Cappai, A.; Velluti, C.; Salvi, M. Improving physical quality of life with group physical activity in the adjunctive treatment of major depressive disorder. Clin. Pract. Epidemol. Ment. Health 2008, 4, 1.
88. Calabrese, J. R.; Keck, P. E., Jr.; McElroy, S. L.; Shelton, M. D. A pilot study of topiramate as monotherapy in the treatment of acute mania. J. Clin. Psychopharmacol. 2001, 21, 340-342.
89. Shaldubina, A.; Einat, H.; Szechtman, H.; Shimon, H.; Belmaker, R. H. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J. Neural Transm. 2002, 109, 433-440.
90. Ghelardoni, S.; Bazinet, R. P.; Rapoport, S. I.; Bosetti, F. Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology (Berl). 2005, 180, 523-529.
91. Kushner, S. F.; Khan, A.; Lane, R.; Olson, W. H. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 2006, 8, 15-27.
92. Hashimoto, K.; Sawa, A.; Iyo, M. Increased Levels of Glutamate in Brains from Patients with Mood Disorders. Biol. Psychiatry 2007, 62, 1310-6.
93. Itokawa, M.; Yamada, K.; Iwayama-Shigeno, Y.; Ishitsuka, Y.; Detera-Wadleigh, S.; Yoshikawa, T. Genetic analysis of a functional GRIN2A promoter (GT)n repeat in bipolar disorder pedigrees in humans. Neurosci. Lett. 2003, 345, 53-56.
94. Martucci, L.; Wong, A. H.; De Luca, V.; Likhodi, O.; Wong, G. W.; King, N.; Kennedy, J. L. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr. Res. 2006, 84, 214-221.
95. Scarr, E.; Pavey, G.; Sundram, S.; MacKinnon, A.; Dean, B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord. 2003, 5, 257-264.
96. Gascon, S.; Deogracias, R.; Sobrado, M.; Roda, J. M.; Renart, J.; Rodriguez-Pena, A.; Diaz-Guerra, M. Transcription of the NR1 subunit of the N-methyl-D-aspartate receptor is down-regulated by excitotoxic stimulation and cerebral ischemia. J. Biol. Chem. 2005, 280, 35018-35027.
97. Ciabarra, A. M.; Sullivan, J. M.; Gahn, L. G.; Pecht, G.; Heinemann, S.; Sevarino, K. A. Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J. Neurosci. 1995, 15, 6498-6508.
98. Sucher, N. J.; Akbarian, S.; Chi, C. L.; Leclerc, C. L.; Awobuluyi, M.; Deitcher, D. L.; Wu, M. K.; Yuan, J. P.; Jones, E. G.; Lipton, S. A. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J. Neurosci. 1995, 15, 6509-6520.
99. Das, S.; Sasaki, Y. F.; Rothe, T.; Premkumar, L. S.; Takasu, M.; Crandall, J. E.; Dikkes, P.; Conner, D. A.; Rayudu, P. V.; Cheung, W.; Chen, H. S.; Lipton, S. A.; Nakanishi, N. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 1998, 393, 377-381.
100. Banasr, M.; Chowdhury, G. M.; Terwilliger, R.; Newton, S. S.; Duman, R. S.; Behar, K. L.; Sanacora, G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol. Psychiatry 2008, [Epub ahead of print].
101. Zhou, H. R.; Islam, Z.; Pestka, J. J. Kinetics of lipopolysaccharide-induced transcription factor activation/inactivation and relation to proinflammatory gene expression in the murine spleen. Toxicol. Appl. Pharmacol. 2003, 187, 147-161.
102. Rosenberger, T. A.; Villacreses, N. E.; Hovda, J. T.; Bosetti, F.; Weerasinghe, G.; Wine, R. N.; Harry, G. J.; Rapoport, S. I. Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide. J. Neurochem. 2004, 88, 1168-1178.
103. Chang, Y. C.; Kim, H. W.; Rapoport, S. I.; Rao, J. S. Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: cross-talk between excitotoxicity and neuroinflammation. Neurochem. Res. 2008, 33, 2318-2323.
104. Petitto, J. M.; Lysle, D. T.; Gariepy, J. L.; Lewis, M. H. Association of genetic differences in social behavior and cellular immune responsiveness: effects of social experience. Brain. Behav. Immun. 1994, 8, 111-122.
105. Gasparotto, O. C.; Carobrez, S. G.; Bohus, B. G. Effects of LPS on the behavioural stress response of genetically selected aggressive and nonaggressive wild house mice. Behav. Brain Res. 2007, 183, 52-59.
106. Zalcman, S. S.; Siegel, A. The neurobiology of aggression and rage: role of cytokines. Brain. Behav. Immun. 2006, 20, 507-514.
107. Siegel, A.; Bhatt, S.; Bhatt, R.; Zalcman, S. S. The neurobiological bases for development of pharmacological treatments of aggressive disorders. Curr. Neuropharmacol. 2007, 5, 135-147.
108. Stoll, A. L.; Severus, W. E.; Freeman, M. P.; Rueter, S.; Zboyan, H. A.; Diamond, E.; Cress, K. K.; Marangell, L. B. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 1999, 56, 407-412.
109. Diau, G. Y.; Hsieh, A. T.; Sarkadi-Nagy, E. A.; Wijendran, V.; Nathanielsz, P. W.; Brenna, J. T. The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med. 2005, 3, 11.
110. Salem, N., Jr.; Wegher, B.; Mena, P.; Uauy, R. Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. Proc. Natl. Acad. Sci. USA 1996, 93, 49-54.
111. Zarate, C. A., Jr.; Quiroz, J. A.; Singh, J. B.; Denicoff, K. D.; De Jesus, G.; Luckenbaugh, D. A.; Charney, D. S.; Manji, H. K. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry 2005, 57, 430-432.